These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23938771)

  • 1. Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.
    Dalençon F
    Hum Vaccin Immunother; 2013 Sep; 9(9):2013-4. PubMed ID: 23938771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern Vaccines/Adjuvants Formulation--Session 2 (Plenary II): May 15-17, 2013--Lausanne, Switzerland.
    Collin N
    Hum Vaccin Immunother; 2013 Sep; 9(9):2015-6. PubMed ID: 23966098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
    Fox CB
    Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.
    Tupin E
    Hum Vaccin Immunother; 2013 Sep; 9(9):2009-12. PubMed ID: 23896583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are we entering a new age for human vaccine adjuvants?
    O'Hagan DT; Fox CB
    Expert Rev Vaccines; 2015 Jul; 14(7):909-11. PubMed ID: 25947042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaps in knowledge and prospects for research of adjuvanted vaccines.
    Seder R; Reed SG; O'Hagan D; Malyala P; D'Oro U; Laera D; Abrignani S; Cerundolo V; Steinman L; Bertholet S
    Vaccine; 2015 Jun; 33 Suppl 2():B40-3. PubMed ID: 26022566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
    Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
    Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Vaccine Formulation Laboratory: a platform for access to adjuvants.
    Collin N; Dubois PM
    Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One does not fit all: new adjuvants are needed and vaccine formulation is critical.
    Korsholm KS
    Expert Rev Vaccines; 2011 Jan; 10(1):45-8. PubMed ID: 21162619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The path forward.
    De Gregorio E
    Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development.
    Tom JK; Albin TJ; Manna S; Moser BA; Steinhardt RC; Esser-Kahn AP
    Trends Biotechnol; 2019 Apr; 37(4):373-388. PubMed ID: 30470547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation adjuvants--from empiricism to rational design.
    O'Hagan DT; Fox CB
    Vaccine; 2015 Jun; 33 Suppl 2():B14-20. PubMed ID: 26022561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
    Chauhan N; Tiwari S; Iype T; Jain U
    Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in vaccine development.
    Moyle PM
    Curr Protoc Microbiol; 2015 Feb; 36():18.1.1-18.1.26. PubMed ID: 25641099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation.
    Garg R; Latimer L; Simko E; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    J Gen Virol; 2014 Feb; 95(Pt 2):301-306. PubMed ID: 24136365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal Vaccine Development Based on Liposome Technology.
    Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
    J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.
    Marciani DJ
    Drug Discov Today; 2003 Oct; 8(20):934-43. PubMed ID: 14554157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in adjuvant discovery for peptide-based subunit vaccines.
    Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I
    Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
    Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
    Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice.
    Zheng Y; Bian L; Zhao H; Liu Y; Lu J; Liu D; Zhang K; Song Y; Luo Y; Jiang C; Chen Y; Zhang Y; Kong W
    Front Immunol; 2020; 11():526965. PubMed ID: 33013922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.